Quality of Life and Survivorship Care in Patients Undergoing HIPEC (HOPE)
Primary Outcome Measures:
- Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population [ Time Frame: T1, Baseline/pre-HIPEC orientation, Day 0 ] [ Designated as safety issue: No ]
Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI) - Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population [ Time Frame: T2, after HIPEC orientation, Day 0 ] [ Designated as safety issue: No ]
Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI) - Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population [ Time Frame: T3, 1 month post HIPEC, Average Day 30 ] [ Designated as safety issue: No ]
Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI) - Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population [ Time Frame: T4, 3 months post HIPEC, Average Day 90 ] [ Designated as safety issue: No ]
Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
Secondary Outcome Measures:
- Reduce pre-treatment distress and anxiety [ Time Frame: Pre-HIPEC, Day 0 ] [ Designated as safety issue: No ]
Compared t-tests will be conducted for the CESD and STAI (state anxiety subscale). - Improve pre-treatment self-efficacy [ Time Frame: Pre-HIPEC, Day 0 ] [ Designated as safety issue: No ]
Mean scores on the distress thermometer will be compared as well as individual patient changes. - Provide educational material delivered by the SRB [ Time Frame: Pre-HIPEC, Day 0 ] [ Designated as safety issue: No ]
Form to assess utility of the Survivorship Resource Book - Improve overall post-operative QOL ratings at 3 months, relative to discharge [ Time Frame: T4, 3 months post discharge, Average Day 90 ] [ Designated as safety issue: No ]
Improve post-operative QOL ratings at 3 months, relative to discharge. Repeated measures analysis of covariance (ANCOVA) will be utilized with the FACT scales.
Detailed Description
Primary Objectives:
- Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population.
Secondary Objectives:
- Reduce pre-treatment distress and anxiety. II. Improve pre-treatment self-efficacy. III. Provide educational material delivered by the SRB. IV. Improve overall post-operative QOL ratings at 3 months, relative to discharge.
Outline: Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. . After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks, and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
Criteria
- Inclusion
-
- Patients who undergo CS and HIPEC for peritoneal surface malignancy
Quick Facts
Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact